Blood products company Haemonetics (NYSE:HAE). reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.8% year on year to $346.4 million. Its non-GAAP profit of $1.29 per ...

Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations website at ...

Haemonetics gains attention after softer earnings highlighted the impact of unusual accounting items and long-term healthcare ...

View Haemonetics Corporation HAE stock quote prices, financial information, real-time forecasts, and company news from CNN.

What Happened? Shares of blood products company Haemonetics (NYSE:HAE) jumped 4.1% in the afternoon session after BofA Securities upgraded its rating on the company to Buy from Neutral and raised its ...

Haemonetics (HAE) shares rose for the third consecutive session on Friday after Bank of America upgraded the blood management solutions provider to Buy from Neutral, arguing that the MedTech has ...

Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst ...

Haemonetics (NYSE:HAE) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

Aristotle Capital Boston, LLC, an investment advisor, released its first-quarter 2026 investor letter for “Small Cap Equity ...

We believe that Haemonetics stock, best known for its blood and plasma supplies and services, is a good buying opportunity at the present time. HAE stock trades near $70 currently and it is, in fact, ...

Haemonetics stock (NYSE: HAE), best known for its blood and plasma supplies and services, has fallen by 3.5% in the last week, while it is down 7% over the last ten days. HAE stock has been on a ...